Integer (NYSE:ITGR) Given Buy Rating at Benchmark

Benchmark restated their buy rating on shares of Integer (NYSE:ITGR) in a research note issued to investors on Friday morning, Benzinga reports. They currently have a $130.00 target price on the medical equipment provider’s stock.

Other analysts also recently issued research reports about the company. CL King initiated coverage on Integer in a research report on Thursday, March 14th. They issued a buy rating and a $137.00 target price on the stock. KeyCorp lifted their target price on Integer from $123.00 to $139.00 and gave the company an overweight rating in a research report on Tuesday, April 9th. Finally, Bank of America raised Integer from a neutral rating to a buy rating and lifted their target price for the company from $105.00 to $135.00 in a research report on Monday, April 15th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus target price of $120.50.

Integer Stock Performance

Shares of Integer stock opened at $109.58 on Friday. The firm has a market cap of $3.67 billion, a price-to-earnings ratio of 37.92, a price-to-earnings-growth ratio of 1.54 and a beta of 1.10. The stock’s 50-day moving average is $113.11 and its 200-day moving average is $99.78. Integer has a one year low of $69.40 and a one year high of $123.99. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.32 and a quick ratio of 1.71.

Integer (NYSE:ITGR) last issued its quarterly earnings results on Thursday, April 25th. The medical equipment provider reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $1.12 by $0.02. The company had revenue of $414.80 million for the quarter, compared to analyst estimates of $412.78 million. Integer had a return on equity of 11.25% and a net margin of 6.01%. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.87 earnings per share. Equities analysts predict that Integer will post 5.31 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Integer

A number of institutional investors have recently bought and sold shares of the business. Handelsbanken Fonder AB increased its position in Integer by 1.7% during the fourth quarter. Handelsbanken Fonder AB now owns 5,837 shares of the medical equipment provider’s stock worth $578,000 after buying an additional 100 shares during the last quarter. Cornercap Investment Counsel Inc. increased its position in Integer by 1.0% during the fourth quarter. Cornercap Investment Counsel Inc. now owns 12,014 shares of the medical equipment provider’s stock worth $1,190,000 after buying an additional 121 shares during the last quarter. Arizona State Retirement System increased its position in Integer by 1.4% during the third quarter. Arizona State Retirement System now owns 9,474 shares of the medical equipment provider’s stock worth $743,000 after buying an additional 131 shares during the last quarter. Quadrant Capital Group LLC grew its position in shares of Integer by 10.2% in the fourth quarter. Quadrant Capital Group LLC now owns 1,427 shares of the medical equipment provider’s stock valued at $141,000 after purchasing an additional 132 shares during the last quarter. Finally, Janney Montgomery Scott LLC grew its position in shares of Integer by 1.5% in the third quarter. Janney Montgomery Scott LLC now owns 9,507 shares of the medical equipment provider’s stock valued at $746,000 after purchasing an additional 142 shares during the last quarter. Institutional investors and hedge funds own 99.29% of the company’s stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.